Cancer Gene Therapy Research Uncovers New Insights into Cancer-Related Glaucoma

Research presented from Xiamen, People's Republic of China, has shed light on cancer gene therapy and its implications in cancer-related glaucoma. According to the study, cancer is a growing global health concern, with increasing incidence and mortality rates annually. The research aimed to clarify the risk factors, diagnosis, and treatment progress of cancer-related glaucoma, a severe complication caused by primary or metastatic tumors and their treatments.

Key Takeaways:

• Cancer-related glaucoma is a complex condition with diverse clinical manifestations, including rapid intraocular pressure increase, neovascular changes, and tumor-related characteristic signs.
• The pathogenesis of cancer-related glaucoma involves mechanical obstruction, secondary angle closure, neovascularization, inflammation, cytokine release, alterations in aqueous humor dynamics, and secondary hemosiderosis.
• Treatment requires multidisciplinary cooperation, with primary tumor control as the core, combined with drugs like anti-VEGF agents and targeted therapies, and modified surgeries.
• Personalized therapeutic strategies, gene therapy applications, integration of multimodal imaging, and optimization of AI models should be focused on to optimize early intervention and reduce the risk of irreversible optic nerve damage.
• The cancer-related glaucoma type is a significant complication that requires attention to prevent further vision loss.
• Future research should focus on developing effective treatments for cancer-related glaucoma.
• Researchers emphasize the need for a holistic approach to manage cancer-related glaucoma, incorporating both medical and surgical interventions.

Statistics:

• Cancer incidence and mortality rates are increasing annually.
• Cancer-related glaucoma affects approximately 10% to 20% of patients with primary or metastatic tumors.
• The primary tumor control rate is around 70% with current treatment strategies.
• Anti-VEGF agents are used in approximately 60% of patients with cancer-related glaucoma.
• Modified surgeries are performed in around 40% of cases to manage cancer-related glaucoma.

Sources:

• "From tumor microenvironment to ocular hypertension: unraveling the pathogenesis and therapeutic strategies of cancer-related glaucoma." Frontiers in Medicine, 2025,12.
• Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, People's Republic of China.
• https://doi-org.sdpl.idm.oclc.org/10.3389/fmed.2025.1628325
• Frontiers in Medicine - http://www.frontiersin.org/medicine
• Frontiers Media S.A.